Patent application number | Description | Published |
20110033794 | TONER, METHOD FOR PRODUCING THE SAME, AND PROCESS CARTRIDGE - A toner containing a binder, a colorant, and a wax having a molecular chain consisting of C—H bond and C—C bond, wherein the mass reduction of the wax at 165° C. is 10% by mass or less, and the total amount of the wax in the toner measured by a DSC method is 1% by mass to 8% by mass, wherein a ratio, Sbet/SF, of a BET specific surface area (Sbet) of the toner to an average circularity (SF) of the toner is 1.0 m | 02-10-2011 |
20110255899 | TONER, DEVELOPER, TONER CONTAINER, PROCESS CARTRIDGE AND IMAGE FORMING APPARATUS - A toner, including a binder; a colorant; and a wax including a molecular chain constituted of only a C—H bond and a C—C bond, and having a melting point of from 50 to 78° C. and a melt viscosity of from 5 to 15 mPa·S at 140° C., wherein the toner has a weight reduction rate of from 0.001 to 0.1% by weight/min when measured by TGA (Thermogarvimetric Analysis) method in an atmosphere at 165° C. for 10 min. | 10-20-2011 |
20110262856 | TONER CONTAINING CRYSTALLINE POLYESTER - A toner including a binder resin which contains a crystalline polyester resin and a non-crystalline polyester resin, wherein the crystalline polyester resin has at least two diffraction peaks in a range of 20°<2θ<25° as detected by X-ray diffraction measurement, and has a melting point which is 60° C. or higher but lower than 80° C., and wherein the diffraction peaks each have a half width which is less than 1.0°. | 10-27-2011 |
20110305986 | TONER, DEVELOPER, AND IMAGE FORMING METHOD - A toner containing a binder resin, a colorant, and a releasing agent, wherein the colorant contains a mixed crystal of a C. I. PIGMENT YELLOW 185 and a C. I. PIGMENT YELLOW 139, and wherein a mass ratio of the C. I. PIGMENT YELLOW 185 to the C. I. PIGMENT YELLOW 139 (mass of the C. I. PIGMENT YELLOW 185/mass of the C. I. PIGMENT YELLOW 139) in the toner is 95/5 to 50/50. | 12-15-2011 |
20120064445 | IMAGE FORMING APPARATUS AND TONER FOR DEVELOPING LATENT ELECTROSTATIC IMAGES - A toner which contains: toner base particles having Dv of 4.0-6.0 μm; and two or more additives on surfaces of the toner base particles, where the additives contains Additives A and B, wherein the toner base particles are obtained by the method containing: dispersing, in an aqueous medium, an oil phase in which at least one of a crystalline polyester resin and a non-crystalline polyester resin is contained in an organic solvent, to prepare a dispersion liquid; and removing the organic solvent from the dispersion liquid, and wherein the Additive A has the largest average primary particle diameter in the additives and has CA of 5-10% where the CA is determined by the formula A, and the Additive B has the smallest average primary particle diameter in the additives and has CB of 45-100% where the CB is determined by the formula B. | 03-15-2012 |
20120264043 | ELECTROSTATIC IMAGE DEVELOPING TONER - An electrostatic image developing toner including: a binder resin; a colorant; and a wax, wherein the intensity ratio of an absorbance at 2,850 cm | 10-18-2012 |
20130022371 | TONER FOR ELECTROSTATIC CHARGE DEVELOPMENT - To provide a toner, which contains a binder resin, a colorant, and a releasing agent, wherein the binder resin contains a low molecular weight resin component, where the low molecular weight resin component has a resin softening coefficient (A), represented by the following formula (1), satisfying A>0.165, and has storage elastic modulus (dyne/cm | 01-24-2013 |
20130224648 | ELECTROSTATIC IMAGE DEVELOPING TONER PARTICLES AND DEVELOPER - Electrostatic image developing toner particles including: a crystalline polyester resin; a non-crystalline polyester resin; a releasing agent; and a colorant, wherein the electrostatic image developing toner particles have a glass transition temperature of 40° C. to 60° C. where the glass transition temperature is measured with a differential scanning calorimeter (DSC), and wherein the electrostatic image developing toner particles have an adhesive force between the toner particles of 1.4 mN to 2.2 mN where the adhesive force between the toner particles is measured after the electrostatic image developing toner particles have been stored at 50° C. | 08-29-2013 |
20130243488 | TONER, TWO-COMPONENT DEVELOPER, AND IMAGE FORMING APPARATUS - A toner including: toner base particles; and external additive, the toner base particles each comprising binder resin and colorant, wherein the external additive comprises coalesced particles, the coalesced particles are each a non-spherical secondary particle in which primary particles are coalesced together, and an index of a particle size distribution of the coalesced particles is expressed by Formula (1): | 09-19-2013 |
20130244155 | TONER, TWO-COMPONENT DEVELOPER AND IMAGE FORMING APPARATUS - A toner including: toner base particles; and an external additive, the toner base particles each comprising a binder resin and a colorant, wherein the external additive comprises non-spherical particles and spherical particles, wherein the non-spherical particles are each a secondary particle in which spherical primary particles are coalesced together, and wherein the non-spherical particles and the spherical particles in the external additive satisfy a relationship expressed by the following formula (1): | 09-19-2013 |
20130244156 | TONER FOR DEVELOPING ELECTROSTATIC IMAGE, TWO-COMPONENT DEVELOPER AND IMAGE FORMING APPARATUS - A toner for developing an electrostatic image, including: toner base particles each including a binder resin and a releasing agent; and inorganic fine particles, wherein the toner includes the inorganic fine particles as an external additive on a surface of the toner base particle, wherein the toner base particles have a BET specific surface area of 2.5 m | 09-19-2013 |
20130244158 | TONER SET, DEVELOPER SET, AND IMAGE FORMING APPARATUS - A toner set, including: a transparent toner including a binder resin a, a releasing agent a and no colorant; and one or more color toners, each including a binder resin b, a colorant b and a releasing agent b, wherein the binder resin a includes a non-crystalline resin α and a crystalline resin α, the binder resin b includes a non-crystalline resin β and a crystalline resin β, the releasing agent a has an average particle diameter as a long diameter of 0.2 μm to 2.0 μm, and there is a relationship of 1 | 09-19-2013 |
20140072349 | DEVELOPING DEVICE AND IMAGE FORMING APPARATUS - A developing device, including: a developer bearing member, which is disposed opposite to an electrostatic latent image bearing member and which bears thereon a developer for developing an electrostatic latent image formed on the electrostatic latent image bearing member and conveys the developer to a developing region, wherein the developer includes a toner and a carrier, the toner containing: a toner base containing a binder resin and a colorant; and an external additive, wherein the external additive contains coalescent particles each made up of a plurality of coalescing primary particles, and wherein a work function Wc of the carrier and a work function Ws of the developer bearing member satisfy a relationship of the following formula (1): | 03-13-2014 |
20140140731 | TONER, DEVELOPER, IMAGE FORMING APPARATUS AND IMAGE FORMING METHOD - A toner including: a binder resin; a releasing agent; and a colorant, wherein the binder resin contains a crystalline polyester resin and a non-crystalline polyester resin, wherein the releasing agent has an endothermic peak temperature of 60° C. to 80° C. at the second temperature rising in differential scanning calorimetry, and wherein the releasing agent is an ester wax which satisfies the following expressions (1) and (2): 1.1 Pa·s≦η*a≦2.0 Pa·s . . . Expression (1) 0.001≦η*b/η*a≦1.00 . . . Expression (2) where in Expressions (1) and (2), η*a denotes a complex viscosity (Pa·s) determined by measuring a dynamic viscoelasticity of the releasing agent at a measurement frequency of 6.28 rad/s, and η*b denotes a complex viscosity (Pa·s) determined by measuring a dynamic viscoelasticity of the releasing agent at a measurement frequency of 62.8 rad/s. | 05-22-2014 |
20140220485 | TONER, DEVELOPER AND IMAGE FORMING APPARATUS - To provide a toner, which contains silica particles containing first silica particles, and second silica particles, wherein the toner is a toner produced by depositing the silica particles on surfaces of base particles, the first silica particles have an average primary particle diameter of 75 nm to 250 nm, the second silica particles have an average primary particle diameter of 10 nm to 50 nm, a mass ratio of the first silica particles to the base particles is 0.010 to 0.040, a mass ratio of the second silica particles to the base particles is 0.005 to 0.030, a liberation ratio of the silica particles from the toner by a ultrasonic vibration method is 5% by mass to 20% by mass, and an amount of particles having primary particle diameters of 30 nm or smaller in the silica particles librated from the toner by the ultrasonic vibration method is 20% by number or less. | 08-07-2014 |
20140234767 | ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER - Provided is an electrostatic charge image developing toner, including: toner base particles including a polyester resin as a binder resin; and an external additive on the surface of the toner base particles. The external additive includes silica. The silica is produced by sol-gel method, and is aspherical. The percentage of change in the specific surface area of the toner when it is stored under high-temperature, high-humidity conditions is from 25% to 45%. | 08-21-2014 |
20140348546 | TONER HOUSING CONTAINER AND IMAGE FORMING APPARATUS - Toner housing container includes: container body mountable on toner conveying device and housing toner supplied into toner conveying device; conveying portion provided in container body and conveying toner from longer direction one end of container body to other end at which container opening portion is provided; pipe receiving port provided at container opening portion and receiving conveying pipe fixed to toner conveying device; and uplifting portion to move toner conveyed by conveying portion toward toner receiving port of conveying pipe. Toner has loose apparent density of 0.28 g/cm | 11-27-2014 |
20150104739 | TONER, DEVELOPER, AND IMAGE FORMING APPARATUS - A toner, containing: toner base particles; and an external additive, the toner base particles each including a binder resin and a releasing agent, wherein the external additive includes non-spherical coalesced particles in each of which primary particles are coalesced together, and wherein the coalesced particles satisfy the following formula (1): Nx/1,000×100≦30% where Nx is a number of the primary particles present alone relative to 1,000 of the coalesced particles, as observed under a scanning electron microscope after stirring 0.5 g of the coalesced particles and 49.5 g of a carrier placed in a 50 mL bottle for 10 minutes by means of a mixing and stirring device at 67 Hz. | 04-16-2015 |
20150198902 | STATIC CHARGE IMAGE DEVELOPING TONER AND IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE USING SAME - Provided is a static charge image developing toner of which flowing start temperatures (Tfb) measured with a flow tester satisfy relational formulae below: | 07-16-2015 |
20150261144 | IMAGE FORMING APPARATUS - An image forming apparatus, including: photoconductor; charging unit; exposing unit; developing unit containing toner; transfer unit; and fixing unit, wherein the toner includes external additive and base particles containing binder resin, colorant, and release agent, the toner has melt viscosity at 100° C. of 500 Pa·s to 8,000 Pa·s and the release agent has melt viscosity at 100° C. of 20 mPa·s to 30 mPa·s, the fixing unit includes fixing member that has roller or belt shape and contacts toner image transferred onto recording medium, and the fixing member includes release layer on surface thereof that is to be brought into contact with the toner image transferred onto the recording medium, and wherein the release layer satisfies the following expressions: | 09-17-2015 |
Patent application number | Description | Published |
20100003254 | Antibody Substituting for Function of Blood Coagulation Factor VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 01-07-2010 |
20110098450 | Antibody Molecules - The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions. | 04-28-2011 |
20110245473 | Anti-IL-6 Receptor Antibody - The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations. | 10-06-2011 |
20120237517 | Antibody Substituting for Function of Blood Coagulation Factor VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 09-20-2012 |
20120253016 | ANTIBODY MOLECULES THAT BIND TO IL-6 RECEPTOR - The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions. | 10-04-2012 |
20130317203 | Anti-IL-6 Receptor Antibody - The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations. | 11-28-2013 |
20130330345 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII - Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered. | 12-12-2013 |
20140037632 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered. | 02-06-2014 |
20140370018 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered. | 12-18-2014 |